TrialBMJ open ophthalmology2026

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration.

Sigrid Balser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.